Format

Send to

Choose Destination
Pharmacol Res. 2014 Oct;88:99-106. doi: 10.1016/j.phrs.2013.12.002. Epub 2013 Dec 21.

The pharmacogenomics of statins.

Author information

1
Faculty of Pharmacy, University of Sydney, NSW, Australia. Electronic address: ingrid.gelissen@sydney.edu.au.
2
Faculty of Pharmacy, University of Sydney, NSW, Australia; Centre for Education and Research on Ageing, Concord Hospital, Sydney, NSW, Australia.

Abstract

The statin class of cholesterol-lowering drugs have been used for decades to successfully lower plasma cholesterol concentrations and cardiovascular risk. Adverse effects of statins are generally considered mild, but increase with age of patients and polypharmacy. One aspect of statin therapy that is still difficult for prescribers to predict is the individual's response to statin therapy. Recent advances in the field of pharmacogenomics have indicated variants of candidate genes that affect statin efficacy and safety. In this review, a number of candidates that affect statin pharmacokinetics and pharmacodynamics are discussed. Some of these candidates, in particular those involved in import and efflux of statins, have now been linked to increased risk of side effects. Furthermore, pharmacogenomic studies continue to reveal new players that are involved in the fine-tuning of the complex regulation of cholesterol homeostasis and response to statins.

KEYWORDS:

Drug metabolism; Drug transport; LDL-cholesterol; Pharmacogenomics; Statins

PMID:
24365577
DOI:
10.1016/j.phrs.2013.12.002
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center